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This review summarizes and integrates research on vitamin D and CD4+ T-lymphocyte
biology to develop new mechanistic insights into the molecular etiology of autoimmune
disease. A deep understanding of molecular mechanisms relevant to gene–environment
interactions is needed to deliver etiology-based autoimmune disease prevention and treat-
ment strategies. Evidence linking sunlight, vitamin D, and the risk of multiple sclerosis and
type 1 diabetes is summarized to develop the thesis that vitamin D is the environmen-
tal factor that most strongly influences autoimmune disease development. Evidence for
CD4+ T-cell involvement in autoimmune disease pathogenesis and for paracrine calcitriol
signaling to CD4+ T lymphocytes is summarized to support the thesis that calcitriol is sun-
light’s main protective signal transducer in autoimmune disease risk. Animal modeling and
human mechanistic data are summarized to support the view that vitamin D probably influ-
ences thymic negative selection, effector Th1 and Th17 pathogenesis and responsiveness
to extrinsic cell death signals, FoxP3+CD4+ T-regulatory cell and CD4+ T-regulatory cell
type 1 (Tr1) cell functions, and a Th1–Tr1 switch. The proposed Th1–Tr1 switch appears to
bridge two stable, self-reinforcing immune states, pro- and anti-inflammatory, each with a
characteristic gene regulatory network. The bi-stable switch would enable T cells to inte-
grate signals from pathogens, hormones, cell–cell interactions, and soluble mediators and
respond in a biologically appropriate manner. Finally, unanswered questions and potentially
informative future research directions are highlighted to speed delivery of etiology-based
strategies to reduce autoimmune disease.
Keywords: vitamin D, CD4-positiveT lymphocytes, autoimmune diseases, multiple sclerosis, type 1 diabetes
INTRODUCTION
Autoimmune diseases afflict ~50 million Americans and con-
tribute>$100 billion to US health care costs (1). The global burden
has risen with the near tripling in the last half-century of multiple
sclerosis (MS) (2, 3), type 1 diabetes (T1D) (4), and other autoim-
mune diseases. A deep understanding of disease mechanisms will
be needed to deliver etiology-based strategies to reverse this vexing
trend. Indeed,“functional and mechanistic work on the molecular
etiology of disease remains one of the major challenges in modern
biology” (5).
This review highlights recent advances in vitamin D and
T-lymphocyte biology in an effort to harness vitamin D’s
potential to reduce the impact of autoimmune diseases. Gene–
environment interactions, sunlight and vitamin D, and T
Abbreviations: 25-OHD3, 25-hydroxyvitamin D3; APC, antigen-presenting
cells; calcitriol, 1α,25-dihydroxyvitamin D3; CNS, central nervous system;
CTLA4, cytotoxic T-lymphocyte antigen 4; DC, dendritic cell; EAE, experimen-
tal autoimmune encephalomyelitis; EAU, experimental autoimmune uveitis; EBV,
Epstein-Barr virus; IFN, interferon; IL, interleukin; MHC, major histocompatibility
complex; MRI, magnetic resonance imaging; MS, multiple sclerosis; NOD, non-
obese diabetic; RANK, receptor-activator of NF-kappaB; RANKL, receptor-activator
of NF-kappaB ligand; T1D, type 1 diabetes; TCR, T-cell receptor; Th, T helper; TLR,
Toll-like receptor; Tr1, T-regulatory cell type 1; Treg, T-regulatory; TYK2, tyrosine
kinase 2; UV, ultraviolet; VDR, vitamin D receptor; VDRE, vitamin D response
element.
lymphocytes as autoimmune disease initiators and vitamin D
targets are discussed to explain the rationale for reviewing vit-
amin D mechanisms in T cells. Research on vitamin D regu-
lation of thymocyte selection, Th1 and Th17 cells, T-cell pro-
gramed cell death, and T-regulatory (Treg) cells is summa-
rized and integrated into model mechanisms. Finally, unan-
swered questions relating to vitamin D mechanisms in CD4+
T cells are highlighted to promote further research that may
lead to a deeper understanding of autoimmune disease molecular
etiology.
GENES, SUNLIGHT, VITAMIN D, AND T LYMPHOCYTES
AUTOIMMUNE DISEASES
Autoimmune diseases represent a failure of self-identification
leading to an immune-mediated assault on host tissues. More than
100 autoimmune syndromes exist (1). We drew mainly on MS
and T1D research because intensive investigation has generated
detailed insights into vitamin D mechanisms in these diseases and
provided valuable guidance for research on other autoimmune
diseases. Other autoimmune diseases are included where robust
mechanistic data exist. A recent chapter (6) and a review (7) have
summarized vitamin D mechanisms in autoimmune diseases more
generally.
Multiple sclerosis and T1D have distinct target organs, genetic
risk factors, onset ages, and female to male ratios, but target
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organ-specific T cells as initiators unite these diseases. MS is
the leading cause of non-traumatic neurological disability in
young adults. It results from an autoimmune attack on the axon–
myelin unit (8). Neurological dysfunction in MS is attributed to
focal demyelinated lesions in the central nervous system (CNS).
The neurodegenerative process is believed to occur sub-clinically
before the disease is typically diagnosed in the third decade of life.
Most MS patients have a relapsing-remitting form of the disease,
and among them, women outnumber men 3:1.
Type 1 diabetes is a common chronic disease of childhood
with an onset typically between ages 6 and 15. Boys with T1D
slightly outnumber girls. T1D results from an autoimmune attack
on insulin-producing pancreatic β-cells (9). Metabolic dysfunc-
tion in T1D is attributed to β-cell destruction and loss of insulin
production and blood glucose control. The β-cell degenerative
process is also believed to occur sub-clinically before a T1D diag-
nosis, when as much as 70% of β-cell mass has been destroyed
and insulin supply no longer meets demand (10). We searched
for analogies between MS and T1D that might reveal over-arching
environmental influences on T lymphocytes in autoimmunity.
GENE–ENVIRONMENT INTERACTIONS IN AUTOIMMUNE DISEASE
Interacting genetic, environmental, and hormonal influences drive
autoimmune disease. There is a weak genetic component in
autoimmune disease susceptibility. MS risk increases a modest
2–6% among first-degree biological relatives of an MS index case
(11), but candidate risk loci are of such modest aggregate influ-
ence that genetic burden scores cannot accurately predict disease
(12, 13). Autoimmune disease discordance between monozygotic
twins is generally between 60 and 75% and cannot be explained
by somatic mosaicism in MS (14), T1D (15), Crohn’s disease (CD)
(16, 17), or systemic lupus erythematosus (SLE) (18). The low
penetrance of candidate risk loci, high monozygotic twin discor-
dance rates, and rapidly rising disease incidence rates underscore
the hypothesis that an autoimmune disease phenotype emerges when
modifiable environmental stressors act on a disease-susceptible geno-
type, and exposure to at least one environmental stressor is increasing.
The key questions are (i) what are the dominant, modifiable envi-
ronmental stressors, (ii) by what mechanisms do they interact
with susceptibility genes to propel the disease process, and (iii)
can mechanistic knowledge of gene–environment interactions be
exploited to craft effective, etiology-based disease prevention and
treatment strategies.
SUNLIGHT EXPOSURE AND RISK OF MS AND T1D DISEASE
There is a large, latitude-linked, non-transmissible environmen-
tal component acting in a female-biased manner at the popula-
tion level that determines whether the MS phenotype emerges
from an MS-susceptible genotype (19, 20). Supporting this inter-
pretation are the gradient in MS prevalence as a function of
latitude (21, 22), alteration of MS risk by migration (23), and
the equivalent MS risk between non-biological relatives of an
MS case and the general population (24). The latitudinal gra-
dient has dissipated as incidence has risen in low latitude regions.
Peak MS prevalence was ~130/105 population in 1960 (21) and
is now ~400/105 (22). Young women have borne the brunt of
rising MS incidence (25, 26). The rise in female MS incidence
implies a significant proportion of new female MS cases may be
preventable (27).
Low sunlight exposure is postulated to be the major latitude-
linked component in MS risk (21). Ultraviolet (UV) irradiance
varies 400-fold with latitude (28), correlating inversely with the
~400-fold variation in MS prevalence (22). UV irradiance also
varies seasonally at high latitudes, where increases in MS disease
activity have been noted lagging seasonal declines in ambient UV
light (29–31). Furthermore, childhood and occupational sunlight
exposure correlated inversely with MS disease risk (32–35) and
mortality (36).
Low sunlight exposure is also postulated to be a major com-
ponent in T1D risk. Globally, T1D incidence varied ~350-fold
(37) correlating inversely with the 400-fold latitudinal variation
in UV irradiance (28). Global T1D incidence is increasing, while
the proportion of T1D patients with the major HLA risk genotype
is decreasing (13), implicating a modifiable environmental factor.
T1D onset peaked between October and January and reached a
nadir between June and August in the northern hemisphere, with
a reverse pattern in the southern hemisphere (38). This correlation
disappeared after adjustment for latitude. The inverse correlation
between ambient winter UV radiation and T1D (r = −0.80) (39)
was nearly as robust as that for MS (r =−0.9) (21). Thus, ambient
UV irradiance is the leading candidate for the large, latitude-linked
environmental risk factor in both MS and T1D (40, 41).
The correlative data are consistent with but do not prove that
low sunlight exposure is a major component in autoimmune dis-
ease risk. Other environmental risk factors have been proposed
(42), but they have markedly smaller effect sizes. For example,
symptomatic Epstein-Barr virus (EBV) infection in adolescence
(mononucleosis), the strongest of the environmental risk factors
that appear to act independently of latitude, season, and UV light
(43), correlates with a two to threefold increase in MS risk (44).
In sharp contrast, residence in a low ambient UV light region cor-
relates with a >100-fold increase in MS risk (22). Whether EBV
infection and UV light are completely independent risk factors is
currently debated (45). As discussed below, genetic data suggest
the VDR gene influences HLA-DRB1 presentation of peptides to
CD4+ T lymphocytes, and structural data show pathogenic T cells
did not distinguish a DRB1*1501-restricted myelin peptide from a
DRB5*0101-restricted EBV peptide suggesting a molecular mim-
icry mechanism underlying pathogenesis. In summary, the UV-
linked component exerts its influence on multiple autoimmune
diseases and on populations with disparate ancestries, distinct
dietary and smoking habits, and dissimilar exposures to infec-
tious and commensal organisms. These qualities of strength and
universality provide the rationale for close investigation of this
component’s identity and mechanisms.
VITAMIN D AND TRANSDUCTION OF SUNLIGHT’S PROTECTIVE
SIGNALS IN MS AND T1D
Vitamin D3 and its hormonal form, 1α,25-dihydroxyvitamin D3
(calcitriol) have been proposed as the major biological transduc-
ers of sunlight’s protective signals in autoimmune disease due to
calcitriol’s ability to selectively regulate T-cell-mediated autoim-
mune responses (46). Evidence supporting this hypothesis has
been reviewed (6, 7, 42, 47, 48). Persuasive evidence for vitamin D
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as sunlight’s signal transducer derives from genetic linkage studies.
Rare loss-of-function mutations in the CYP27B1 gene correlated
with a significantly increased autoimmune disease risk. This asso-
ciation was first reported for T1D (49–54), Addison’s disease (55),
Hashimoto’s thyroiditis, and Graves’ disease (56). It was sub-
sequently reported for MS (57–60). In rare multi-incident MS
families, 35 of 35 cases inherited one defective CYP27B1 allele, an
inheritance pattern with small odds (one in a billion) of occurring
by chance (58). Because CYP27B1 mutations are highly penetrant
but exceedingly rare, they do not contribute genetic risk in the
vast majority of disease cases. In fact, genome-wide association
studies (GWAS) and some case–control studies did not detect an
association between CYP27B1 variants and MS or T1D (61–65).
However, the replicated positive genetic findings indelibly mark
calcitriol synthesis as a key determinant of MS and T1D risk.
Correlations between VDR alleles and MS susceptibility have
also been reported (66–68). An early study found a VDR and
MS association in patients who carried the high-risk HLA-
DRB1*1501 allele (69). Later research identified a putative vitamin
D-responsive element (VDRE; see below) in the HLA-DRB1*1501
promoter (70). The VDR association data have been inconsis-
tent between populations, and some VDR polymorphisms studied
do not have known functional impacts. The VDR FokI polymor-
phism is an exception; VDRF (without the FokI site) encodes a 424
amino acid protein with higher transcriptional activity than the
427 amino acid protein encoded by VDRf (a FokI site in the first
ATG codon) (71, 72). The less active VDRf protein was associated
with higher serum 25-hydroxyvitamin D (25-OHD) levels, lower
MS risk, and lower MS disability (73–76). Another exception is the
Cdx-2G variant, which has 70% reduced promoter activity (77);
this variant correlated with an increased risk of MS in children
who had ≤2 h/day of winter sun exposure (78). GWAS did not
detect a VDR and MS association (61).
Some family studies have also detected linkage between VDR
polymorphisms and T1D, but concerns about inconsistencies
between populations and unknown functional impacts also apply
here (79). Reasoning that a VDR and T1D association might only
be evident if 25-OHD is sufficient to support calcitriol synthesis in
cells relevant to T1D, investigators searched for this association as
a function of latitude (79). They found a VDRF and T1D associa-
tion that varied in strength according to ambient winter UV light.
These data emphasize the importance of analyzing genetic data
in the context of environmental variables. GWAS did not detect a
VDR and T1D association (62, 80).
Intriguing data suggest an epistatic interaction between VDR
alleles and HLA-DR susceptibility loci in T1D as in MS. The
VDRF–T1D association was only evident in patients who carried
the high-risk HLA-DRB1*0301 allele (81). The HLA-DRB1*0301
allele like the HLA-DRB1*1501 allele harbors a putative VDRE
in its promoter (70). Alleles without the putative VDRE were
associated with disease resistance. These parallels suggest an influ-
ence of UV light and vitamin D on HLA-DRB1 gene expression
and presentation to CD4+ T lymphocytes of peptides relevant to
T1D and MS etiology. The nature of the peptides and the tim-
ing and outcome of the presentation event are unknown, but
could relate to thymic tolerance or peripheral T-cell responses to
peptides from infectious agents. In any case, the positive findings
regarding VDR polymorphisms provide genetic support for cal-
citriol and vitamin D receptor (VDR)-regulated transcriptional
events as determinants of MS and T1D risk.
Additional evidence for vitamin D and calcitriol as sunlight’s
signal transducers derives from vitamin D studies. An early study
closely correlated childhood dental disease, serving as an accessible
biomarker of exposure to low vitamin D status (82), with world-
wide MS mortality (r = 0.78, p< 0.002) (83). The first vitamin D3
interventional study to inhibit autoimmune disease was performed
in the murine experimental autoimmune encephalomyelitis (EAE)
model of MS (84). Human case–control studies have correlated
low vitamin D intake and low circulating 25-OHD with high MS
risk (85–87). Importantly, MS risk correlated inversely with circu-
lating 25-OHD independently of personal UV light exposure (88).
Abundant data have now correlated circulating 25-OHD inversely
with MS disease activity (30, 88–94). These data and the CYP27B1
and VDR evidence contradict the view that UV light’s protective
effects in demyelinating disease do not involve vitamin D (95).
In MS patients who had low vitamin D3 levels and were not
taking disease-modifying drugs, supplementary vitamin D3 as a
stand-alone intervention significantly reduced disease progres-
sion (96), and decreased new lesion formation and progression
from optic neuritis to clinically definite MS (97). A vitamin D2
supplementation study did not report similar findings (98), but
significant methodological flaws were noted in that study (99).
Moreover, it is well known that vitamin D2 and vitamin D3 are not
biologically comparable as regards their metabolism and ability to
transcriptionally activate the VDR (100–102). Ongoing clinical
studies are testing whether vitamin D3 as an add-on to disease-
modifying drug therapy will improve drug efficacy (103). While
this is a valid pharmaceutical question, it is separate from the
question of whether vitamin D3 could be an etiology-based inter-
vention to reduce the impact of autoimmune disease. Studies of
vitamin D3 as a stand-alone intervention in individuals who have
low vitamin D3 levels and who are not using disease-modifying
drugs will be needed to address the etiological question. Such
studies are needed and fully justified.
The T1D data also support vitamin D as sunlight’s protective
signal transducer (6, 104, 105). The EURODIAB study correlated
vitamin D3 supplementation in infancy with decreased T1D risk
(odds ratio 0.67) (106), a finding that has been replicated (107).
Finland, at 60–70°N, has the highest T1D incidence in the world
(108). Finnish T1D incidence quadrupled as recommended vita-
min D3 intakes for children decreased from 4000 to 400 IU/day
between 1965 and 2005 (109). Another retrospective analysis
found childhood vitamin D3 supplementation correlated with an
88% lower risk of T1D (110). These data imply that recommending
higher vitamin D3 intakes for pregnant women, infants, and chil-
dren might decrease T1D incidence by>75%. A very recent study
demonstrated that life-long, high-dose vitamin D3 supplemen-
tation significantly reduced spontaneous diabetes in non-obese
diabetic (NOD) mice (111). Finally, vitamin D3 interventions have
improved glycemic control in T1D patients (112–114).
The association of UV irradiance and vitamin D with autoim-
mune disease risk is strong and consistent, shows a dose–response
relationship, is temporally plausible and appears to be univer-
sal with respect to genotypes, dietary and smoking habits, and
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exposure to infectious and commensal organisms. Thus, it is rea-
sonable to suggest that vitamin D is probably the environmental
factor with the greatest influence on the emergence of an autoim-
mune disease phenotype given a disease-susceptible genotype. What
remains to be done to satisfy the Bradford Hill criteria (115)
is to rigorously test this relationship experimentally in humans,
and to uncover plausible biological mechanisms that cohere with
known facts of autoimmune disease. There is a growing consensus
that a vitamin D3 interventional study for autoimmune disease
prevention is needed and fully justified.
T LYMPHOCYTES IN AUTOIMMUNE DISEASE
The effort to decipher protective vitamin D mechanisms in
autoimmunity focuses on T lymphocytes, because in failing to
correctly discriminate between self and non-self, auto-reactive
T cells drive target organ destruction (116). In animal models,
auto-reactive T-cell transfer drives target organ destruction (117).
The role of pathogenic auto-reactive T cells as autoimmune dis-
ease initiators unites these diseases under a common mechanistic
umbrella.
Unequivocal evidence of T-lymphocyte involvement in human
T1D came from transplantation studies. Transplanting pancreatic
tissue from a healthy subject into his/her T1D-affected identical
twin failed as a T1D therapy due to a T-cell-mediated attack on the
transplanted pancreatic tissue unless T-cell immunosuppressive
therapy was administered (118). Evidence for pathogenic CD4+ T
lymphocytes in T1D is now very strong (10, 119).
Original evidence of T-lymphocyte involvement in MS patho-
genesis came from studies showing T cells rapidly migrated
from the periphery into the CNS of MS patients, where clon-
ally restricted, activated T cells accumulated in nascent MS lesions
(120). The T cells from individual MS patients showed dominant
usage of specific T-cell receptor (TCR) alpha and beta chains and
VDJ sequences, and specificity for myelin basic protein (MBP)
peptides presented by HLA class II molecules (121). These obser-
vations argue strongly for involvement of HLA class II-restricted,
auto-reactive CD4+ T cells in MS pathogenesis (122).
Newer experimental approaches have confirmed the pioneering
studies. Analysis of the mRNA transcriptome in blood cells from
MS patients pointed to antigen presentation, the immune synapse,
and T-cell deregulation in MS pathogenesis (123, 124). GWAS
identified genes related to CD4+ T-cell function in regions harbor-
ing putative susceptibility loci (61). Analysis of expression quan-
titative trait loci in autoimmune disease states (125) and genetic
analysis of inter-individual variability in T helper (Th) activation
as a function of ancestry and autoimmune disease susceptibility
(126) also implicated CD4+ Th cell activation in autoimmune
disease pathogenesis. In summary, consideration of gene–
environment interactions, sunlight and vitamin D, and T lympho-
cytes as autoimmune disease initiators provides the rationale for
investigating vitamin D mechanisms in CD4+ T cells in an effort
to understand the molecular etiology of autoimmune disease.
VITAMIN D METABOLISM FROM A T-LYMPHOCYTE
PERSPECTIVE
CALCITRIOL’S NON-CALCEMIC ACTIONS
The vitamin D system is an evolutionarily ancient and versatile
system that coordinates a plethora of biological processes like
cellular metabolism and growth, differentiation and death, organ-
ismal growth, reproduction, and immunity according to sunlight’s
cues. The system’s signal transducing molecules are calcitriol, a
small lipophilic hormone, and the VDR, a hormone-responsive
transcriptional regulator (127). Calcitriol and mammalian VDR
orthologs have functioned as sunlight sensors throughout >750
million years of evolution (128, 129). Many of the ancient organ-
isms lacked calcified structures, so the vitamin D system must have
originally supported non-calcemic functions (129). We focus on
calcitriol’s actions in CD4+ T lymphocytes, but actions in other
tissues, for example promotion of remyelination in the brain (130),
insulin release from the pancreas (131), and intestinal barrier
function in the colon (132), undoubtedly contribute to calcitriol’s
potency as a chronic autoimmune and neurodegenerative disease
inhibitor.
ENZYMES OF VITAMIN D ACTIVATION
Vitamin D metabolism has been well described elsewhere (127,
133–136). Cutaneous vitamin D3 generated by high energy UVB
photons (290–315 nm) provides 90% of the human vitamin D
requirement (108). Vitamin D3 synthesis varies seasonally at high
latitudes, reaching a nadir 2 months after the winter solstice, and
a zenith 2 months after the summer solstice (137). The biological
half-life of 25-OHD3 is ~2 months, so this metabolite effectively
integrates sunlight’s energy signal over time.
AT HIGH LATITUDES, THERE IS A PERIOD OF “LIGHT STARVATION”
WHEN VITAMIN D SYNTHESIS IS NEGLIGIBLE
The higher the latitude, the greater is the period of light starvation.
At 42°N, cutaneous vitamin D synthesis is negligible from Novem-
ber through February (138, 139). Vitamin D synthesis decreases
with increasing skin pigmentation, sunscreen use, and advancing
age. Vitamin D deficiency has rapidly become a worldwide health
problem, due to life-style changes (indoor living and working; sun-
screen use) that have reduced sunlight exposure (140, 141). Now,
more than 75% of Caucasians and>90% of Blacks, Hispanics, and
Asians in the USA have 25-OHD3 <75 nmol/L (30 ng/mL), dou-
ble the number one decade ago (142). The rapid rise in vitamin D
insufficiency correlates temporally with the rapid rise in MS and
T1D incidence.
Two hydroxylation reactions produce the calcitriol from vita-
min D3. The CYP2R1-encoded 25-hydroxylase converts vitamin
D3 into 25-OHD3. The CYP27B1-encoded 1α-hydroxylase con-
verts 25-OHD3 into calcitriol. Calcitriol induces CYP24A1 gene
encoding the 24-hydroxylase to convert calcitriol into inactive cal-
citroic acid. These hydroxylases are cytochrome P450 enzymes
(133, 134). They are encoded in nuclear DNA, but the enzymes
themselves localize to the mitochondrial membrane.
Many chronic diseases provisionally associated with vitamin D
disproportionately impact individuals of African ancestry (AA).
Lower serum 25-OHD in people of AA may be contributing to
these health disparities (143). Serum 25-OHD levels are subject to
genetic regulation (74), and polymorphisms in the GC, DHCR7,
and CYP2R1 genes have been correlated with circulating 25-OHD3
levels in people of European ancestry (EA) (144, 145). Motivated
by the need to understand racial health disparities, recent research
has investigated potential genetic contributions to circulating 25-
OHD3 in AA and EA subjects. The AA subjects had different
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GC alleles encoding the vitamin D-binding protein (DBP) and
lower circulating 25-OHD (146). In addition to binding vitamin D
metabolites, the DBP functions in fatty acid transport,macrophage
activation, and chemotaxis (147). A study of older male subjects
from urban areas confirmed the association of CYP2R1 variants
with serum 25-OHD after correction for vitamin D intake, sea-
son of sampling, BMI, and other variables (148). This association
was more robust in EA than AA subjects. The GC variants were
associated with serum 25-OHD only in the EA subjects. Age, ances-
try, vitamin D intake, and season of sampling explained 19 and
24% of the variance in AA and EA subjects, respectively. Adding
genetic variants to the model explained an additional 1% (AA)
and 4% (EA) of the variance. However, 72% (EA) and 80% (AA)
of the variance was unexplained. Thus, genetic variants are very
minor contributors to racial disparities in serum 25-OHD. The
data also suggest some relevant parameters were either not con-
sidered or were subject to a large error in measurement. Unlike
other reports, skin pigmentation was unrelated to serum 25-OHD
in this study, and UVR exposure was marginally related to serum
25-OHD only in EA subjects. These data indicate serum 25-OHD
derived primarily from vitamin D ingestion, which was assessed
by a questionnaire. The questionnaire may have introduced error.
Whether it assessed vitamin D supplement use was not stated.
The authors previously reported that their EA subjects were more
likely to use vitamin D supplements than the AA subjects (149). To
generate insight into disparities in chronic diseases provisionally
associated with vitamin D, it will be essential to discover dominant
variables by integrating data on age, gender, life-style choices, skin
color, UVR exposure, diet, vitamin D supplement use, and genetic
variation with data on 25-OHD and disease phenotype.
PARACRINE CALCITRIOL SIGNALING TO T CELLS
An important question from a CD4+ T-lymphocyte perspective is
whether the calcitriol signal derives from the kidney (endocrine
signaling) or from tissue-resident cells at sites of inflammation
(paracrine signaling). Calcitriol has been classically viewed as an
endocrine hormone, with renal synthesis and systemic distribu-
tion regulating mineral ion homeostasis and skeletal maintenance
in target tissues. Blood calcitriol levels are maintained within
very narrow limits and show minimal seasonal fluctuation (150),
whereas many autoimmune diseases show fluctuating periods of
relapse and remission. For example, MS disease activity fluctuates
seasonally, correlating with and lagging changes in ambient UVB
sunlight (31) and 25-OHD3 (29). These data are not consistent
with endocrine signaling and instead support paracrine signaling
to T lymphocytes.
Evidence that tissue-resident antigen-presenting cells (APC)
produce calcitriol (151) and T cells express the VDR (152, 153) first
suggested paracrine signaling between immune cells. Adding 25-
OHD3 to cultures altered human T-cell responses only when APC
were present to produce calcitriol (154). The APC required activa-
tion through pathogen-associated pattern recognition receptors,
for example the toll-like receptors (TLR), and/or stimulation by
cytokines, most notably interferon-gamma (IFN-γ), interleukin-2
(IL-2), and IL-15, to become calcitriol producers (136, 154–157).
Calcitriol synthesis has now been shown in many non-calcified
mammalian tissues frequented by roving T lymphocytes, most
notably the skin (158, 159), lung (160), colon (161, 162), brain
(163), placenta, and other reproductive tissues (154, 157, 164), so
paracrine signaling to T cells is a well-established concept. The
CYP27B1 transcripts are more abundant in tissues with barrier
(skin, lung, colon) or reproductive function (maternal decidua,
fetal trophoblast, testis) than in the kidney (158), supporting the
thesis that biological protection at host–environment interfaces
and environmental impacts on reproduction may have driven vit-
amin D system evolution. Available data suggest that paracrine
calcitriol signaling to T cells within tissues is likely the major path-
way by which sunlight exerts its influence on the emergence of an
autoimmune disease phenotype.
It is valuable to consider how calcitriol signaling to CD4+ T
lymphocytes could be compromised causing immune-mediated
tissue damage. Research in the EAE model of MS demonstrated
that insufficient vitamin D3 disrupted calcitriol synthesis in the
CNS (84). Research in the NOD model of T1D demonstrated that
reduced 1α-hydroxylase activity in APC disrupted signaling and
contributed to diabetes (165). As detailed above, CYP27B1 gene
lesions compromise paracrine signaling. It is not widely appre-
ciated that corticosteroids like prednisone (166), prednisolone
(167), or dexamethasone (151) compromise paracrine signaling to
CD4+ T cells because they inhibit calcitriol synthesis by activated
innate immune cells in vivo. Corticosteroid inhibition of calcitriol
synthesis in the airway may have contributed to negative results in
the VIDA trial of vitamin D3 supplementation in asthma patients
who were receiving concurrent corticosteroid therapy (168).
Deregulation of the CYP24A1 gene promoter might also dis-
rupt calcitriol signaling and promote a pro-inflammatory state.
Epigenetic silencing of the CYP24A1 promoter in placental tis-
sue promoted calcitriol accumulation and an immune tolerant
state at the maternal–fetal interface (169, 170). Expression of the
CYP24A1 gene differed between males and females. In the CNS
of rodents with EAE, Cyp24a1 gene expression was higher and
calcitriol responsiveness lower in males than females (84, 171).
Similarly in human T cells from MS patients and healthy controls,
CYP24A1 gene expression was higher and calcitriol responsiveness
was lower in males than females (172). The rodent and human data
suggest males may produce calcitriol at a rate equal to females but
inactivate it faster. Gender differences in CYP24A1 expression and
vitamin D metabolism may underlie the stronger inverse correla-
tion between ambient UV light and MS risk in women compared
to men (173). Estradiol addition to male T cells decreased the
CYP24A1 transcripts and increased calcitriol responsiveness (172),
suggesting estradiol may silence the CYP24A1 gene to promote
calcitriol accumulation (169, 170).
VITAMIN D RECEPTOR EXPRESSION BY CD4+ T
LYMPHOCYTES
VITAMIN D RECEPTOR AND VITAMIN D-RESPONSIVE ELEMENTS
The VDR enables cells to respond to calcitriol. Early researchers
demonstrated a protein with high affinity (K d 0.1 nM) for cal-
citriol in activated human CD4+ T lymphocytes that was later
identified as the VDR (152, 153). The VDR is a nuclear pro-
tein that dimerizes with the retinoid X receptor to regulate gene
expression through VDRE in calcitriol-responsive genes (127).
A VDRE is composed of two hexameric half-sites, arranged as
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direct repeats separated by three random base pairs, for example
GGTTCACGAGGTTCA (174, 175). Depending on the type of cell,
the ligand-activatedVDR–RXR complex recruits either coactivator
complexes and cooperating transcriptional machinery or core-
pressor complexes to determine the nature of the transcriptional
response from VDRE-containing target genes.
Antibody specificity problems have confounded investigations
of VDR protein expression in T cells. All but one of the commer-
cially available antibodies to the VDR bound non-specifically to
cells and tissues from DeMay VDR-null mice (176, 177). These
were confirmed by flow cytometry; all available antibodies either
stained CD4+ T cells from DeMay VDR-null mice or did not yield
a signal (171). The specificity problems have slowed progress in
assessing VDR protein expression in T-cell subsets.
VDR AND CD4+ T-CELL ACTIVATION
Resting and activated T cells differ significantly in VDR expression;
resting cells expressed fewer than 1000 VDR/cell and activation
increased this number 10-fold (178). VDR expression peaked at
48 h post stimulation (179). In rodents, activated CD8+ T cells
had higher VDR expression than CD4+ T cells (180).
Vitamin D receptor expression was needed for optimal human
T-cell activation in vitro (181). Naïve T cells were VDR negative
and responded weakly to TCR stimulation. Weak TCR signaling via
the mitogen-activated protein kinase p38 pathway induced VDR
expression. The T cells subsequently up-regulated phospholipase
C-gamma1 (PLC-γ1) expression 75-fold, enabling them to flux
calcium and become fully activated. PLC-γ1 induction appeared
to be VDR-dependent. The dependence of T-cell activation on
VDR expression has not been demonstrated in vivo.
VDR AND CD4+ T-CELL SUBSETS
Among rodent CD4+ T-cell subsets, IL-4-producing Th2 cells,
IFN-γ-producing Th1 cells, and IL-17-producing Th17 cells all
had abundant Vdr transcripts (182–185). Importantly, a source
of estradiol in female mice (186), and a functional Ifng gene in
male and female mice (171) were essential for Th1 and Th17 cell
Vdr gene expression. Recent data on human Th1 and Th17 cells
produced in vitro also show high Vdr gene expression (179).
Whether CD4+Foxp3+ Treg cells express the VDR is unclear.
Very low Vdr transcript levels were observed in rodent
CD4+Foxp3+ Treg cells produced in vitro (187) and rodent
CD4+EGFP+ Treg cells generated in vivo and flow-sorted from
the spleens of Foxp3EGFP reporter mice (184). Those in vivo stud-
ies revealed an inverse relationship between Foxp3 and Vdr gene
expression, with many Foxp3 transcripts and few Vdr transcripts
in the Foxp3+EGFP+ T cells and the reverse pattern in the EGFP−
T cells. Consistent with low Vdr gene expression, calcitriol had no
impact on flow-sorted CD4+Foxp3+EGFP+ T cells during activa-
tion in vitro (184). Calcitriol also had no impact on CD4+Foxp3+
T-cell proportions in the spleens of WT B6.Cre−VDRfl/fl mice
and B6.Cre+VDRfl/fl mice with CD4+ T-cell-specific Vdr target-
ing, whether or not they were treated with calcitriol (184). These
data suggest fully differentiated, mature rodent CD4+Foxp3+
T cells may not be calcitriol responsive. Contrary to this view,
VDR-dependent down-regulation (187) and up-regulation (185)
of Foxp3 transcription in rodent CD4+Foxp3+ T cells have both
been reported. It will be interesting to learn the molecular details
of Vdr and Foxp3 gene expression control as research in this area
progresses.
CD4+ T CELLS ARE CALCITRIOL TARGETS IN AUTOIMMUNE DISEASE
Selective Vdr gene inactivation experiments in rodents provided
unequivocal evidence that calcitriol targets CD4+ T lympho-
cytes for the purpose of immune system regulation (184). Rec-
iprocal mixed bone marrow chimera studies established that
hematopoietic cell Vdr gene expression was necessary for cal-
citriol to inhibit EAE induction. In fact, chimeric mice lacking
the VDR in hematopoietic cells had a particularly aggressive EAE
disease course. Subsequently, mice with CD4+ T-cell-specific Vdr
targeting were constructed. Evaluation of T-cell subsets in the
periphery of naïve T-cell Vdr-targeted mice assured that this
genetic manipulation did not influence T-cell proportions dur-
ing thymic selection. Neither vitamin D3 nor calcitriol inhibited
EAE induction in mice with CD4+ T-cell-specific Vdr targeting
(184). Thus, EAE data establish that calcitriol exerts protective bio-
logical effects against autoimmunity in vivo through the nuclear
VDR in CD4+ T lymphocytes. These data do not rule out vita-
min D effects on myeloid cells for a pathogen protective immune
response (188). Studies in mice with CD4+ T-cell-specific Vdr
targeting (184), and in humans with loss-of-function mutations
in the VDR gene (189) support the view that the outcome of cal-
citriol signaling within CD4+ T cells is likely a major determinant
of sunlight’s influence on the emergence of an autoimmune disease
phenotype.
VITAMIN D AND THYMOCYTE SELECTION
THYMIC NEGATIVE SELECTION IN AUTOIMMUNE DISEASE
The TCR repertoire is shaped in the mammalian postnatal thy-
mus, and autoimmune disease risk is believed to reflect in
part defects in this process (190). When immature CD4+CD8+
thymocytes engage cortical thymic epithelial cells expressing
self peptides embedded in major histocompatibility complex
(MHC) molecules, those that bind self MHC molecules with
adequate affinity undergo positive selection and develop into
CD4+ or CD8+ T cells. Those that bind with inadequate affinity
for survival signaling undergo apoptosis. Surviving thymocytes
migrate to the thymic medulla where they engage medullary
thymic epithelial cells (mTEC) presenting self peptides, includ-
ing peptides derived from tissue-restricted proteins. Cells that
bind self peptides with high affinity receive apoptotic sig-
nals. The survivors are released to form the pre-immune TCR
repertoire.
An analysis of human autoimmune TCR–peptide–MHC com-
plexes revealed structural anomalies compared to anti-microbial
TCR–peptide–MHC complexes suggesting these TCR may have
escaped thymic negative selection (191). For example, a TCR from
an MS patient recognized both a DRB1*1501-restricted MBP pep-
tide and a DRB5*0101-restricted EBV peptide, suggesting this
TCR may have escaped negative selection become activated by
a pathogen (192). A negative selection failure during early life
is believed to release potentially pathogenic T cells that initi-
ate autoimmune disease when a cross-reactive pathogen peptide
activates them (116).
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VITAMIN D AND THYMIC NEGATIVE SELECTION
Sunlight and vitamin D3 exert their strongest influence on MS
risk during childhood, which coincides with the peak period
for T-cell selection in the postnatal thymus (19). Intriguingly,
recent data quantifying signal joint TCR excision circles (sjTRECs)
in human cord blood T cells as a function of season demon-
strated seasonal variability in thymic output (193). May-born
infants had significantly lower circulating 25-OHD3 and higher
sjTRECs/105 T cells than November-born infants. The sjTRECs
are extra-chromosomal DNA circles formed during TCR gene
rearrangement. They are not replicated as mature peripheral T cells
divide, so they serve as markers of recent thymic emigrants in the
peripheral T-cell repertoire. The data suggest a positive influence
of 25-OHD3 on thymic negative selection. Rigorous investigation
of this possibility is warranted because of the significance such
an influence would have on autoimmune disease risk acquisition,
and the insight it would provide into the timing of risk acquisition
and therefore the timing of etiology-based intervention strategies
to prevent disease.
VITAMIN D AND CD4+ Th1 AND Th17 T CELLS
EFFECTOR T-CELL ANTI-MICROBIAL RESPONSE, CROSS-REACTIVITY,
AND AUTOIMMUNE DISEASE
Exposure to common infectious or commensal organisms triggers
activation of those CD4+ T cells capable of recognizing foreign
antigens in an MHCII context. The biological imperative to pro-
vide adequate immune cover for the host inevitably results in some
effector T-cell cross-reactivity between foreign and self peptides
due to molecular mimicry (116). Peptide antigen diversity is orders
of magnitude larger than TCR diversity (194), and TCR–peptide–
MHC binding shows conformational plasticity, relatively low affin-
ity, and rapid off-kinetics (191, 195). The immune system has
evolved mechanisms to prevent overly aggressive T-cell-mediated
responses that cross-react with host peptides from damaging
host tissue (196). These mechanisms include inhibition of pro-
inflammatory cytokine synthesis, and Treg cell-mediated restric-
tion of T-cell expansion through inhibitory receptors like cytotoxic
T-lymphocyte antigen 4 (CTLA4), induction of T-cell anergy,
and cell death signaling (197). Intriguing new research has docu-
mented a central role for the vitamin D system in the development
of Treg cells and the termination of effector T-cell responses.
MODELING HUMAN AUTOIMMUNE DISEASE
Two animal models have been particularly useful in developing
mechanistic knowledge of direct calcitriol actions in CD4+ T cells,
murine EAE (198, 199), and the NOD mouse (200). These animal
models show strong parallels to their respective human diseases,
especially in the immunological aspects of disease. The parallels
are imperfect, for example regarding the role of human microbial
exposures, because our understanding of human autoimmunity is
incomplete. Nevertheless, hypothesis testing is more facile in ani-
mal models where direct manipulation of contributing factors is
possible. Calcitriol inhibited autoimmune disease in the EAE and
NOD models (201–203). Working back and forth between animal
models and human disease has allowed rapid forward progress to
be made in understanding how the vitamin D system modulates
immunity.
VITAMIN D AND Th1 CELLS
Disease prevention studies in animal models have suggested that
calcitriol directly inhibits encephalitogenic Th1 cells. Calcitriol
inhibited EAE induction (182, 183, 185, 202–205), and targeting
the Vdr gene specifically in CD4+ T cells abrogated this inhibition
(184). However, calcitriol had no effect on CD4+ T-cell priming
in the periphery, myelin-specific T-cell trafficking into the CNS,
or IFN-γ synthesis by freshly explanted, purified CD4+ T cells
from EAE mice (182). Instead, the CNS-infiltrating myelin-specific
CD4+ T cells displayed an anergic phenotype in the calcitriol-
treated mice. These findings have been confirmed (171, 184). In
another strain, calcitriol inhibited EAE induction, but the mech-
anism reported was a decreased Th1 cell frequency in peripheral
lymphoid tissues (206).
The mechanisms involved in amelioration of established
autoimmune disease may differ from those involved in autoim-
mune disease prevention. Administering calcitriol to rodents with
established EAE resulted in very rapid disease remission that cor-
related with fewer CNS CD4+ T cells, loss of IFN-γ-production,
and a significant decrease in CNS pathology (207–210). Induction
of Treg cells in the EAE studies is discussed below.
A short course of oral calcitriol treatment in healthy male vol-
unteers had no measurable effect on circulating IFN-γ (211).
Likewise, in two studies carried out in MS patients, vitamin D3
supplementation had no measurable effect on circulating IFN-γ
(96, 212). In a third study performed in healthy volunteers, vita-
min D3 supplementation decreased the mean percentage of Th1
cells in the circulation from 20 to 17% (213).
VITAMIN D AND Th17 CELLS
Disease prevention studies in animal models have also suggested
that calcitriol directly inhibits encephalitogenic Th17 cells. Exper-
imental autoimmune uveitis (EAU) induced by immunization of
mice with a retinal antigen serves as model for human autoim-
mune uveitis. Oral calcitriol prevented as well as partly reversed
EAU disease (214). In this model, calcitriol treatment in vivo of
mice impaired T-cell commitment to the Th17 lineage as well as
Th17 production of IL-17.
Similar results were reported in the EAE model. The spleens
of calcitriol-treated mice had fewer splenic Th17 cells and lower
IL-17 production than the placebo controls (183, 187). Mice with
global inactivation of the Vdr gene had activated Th17 cells that
overproduced the cytokine (215). Calcitriol treatment reduced
Th17 cells in the CNS in an EAE prevention study (171) and
in two EAE treatment studies (185, 216). Different mechanisms
were suggested to explain these findings (Figure 1A). In one study,
calcitriol did not suppress Il17 gene transcription, but inhibited
Th17 cell IL-17F production in a VDR-dependent manner by a
post-transcriptional mechanism (183). In another study, calcitriol
suppressed Il17 gene transcription by blocking nuclear factor
for activated T cells (NFAT), recruiting histone deacetylase, and
sequestering Runt-related transcription factor 1 (Runx1) (185).
In the third study, elimination of Th17 cells by a programed cell
death mechanism was suggested (216). The reconciliation of these
divergent mechanisms awaits further investigation.
Studies of calcitriol and Th17 cell activity in humans are at an
early stage. Cell culture studies have shown that adding calcitriol to
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FIGURE 1 | Proposed calcitriol mechanisms in effectorTh1,Th17,
and FoxP3+ Treg cells. (A) Calcitriol and IL-17 synthesis in Th17 cells.
Calcitriol inhibited IL-17 synthesis in a VDR-dependent manner by a
post-transcriptional mechanism (183, 187). It also blocked NFAT, recruited
histone deacetylase, and sequestered Runx1 to suppress murine Il17 gene
transcription (185). (B) Calcitriol and effector CD4+ T-cell apoptosis. Calcitriol
increased CD4+ T-cell sensitivity to extrinsic cell death signals that may
have been transduced through the FAS ligand–FAS–caspase-8 and/or the
galectin-9–TIM3–calpain pathways (208–210, 216). (C) Calcitriol and FOXP3
gene transcription. Calcitriol increased the transcription of the murine
FoxP3 (185) and human FOXP3 genes (217). Three VDREs that functioned
as calcitriol-dependent enhancers were identified in a conserved
non-coding sequence (abbreviated CNS in this diagram) between exons 1
and 2. Calcitriol also increased CTLA4 protein expression (218–220).
activated CD4+ T cells reduced the frequency of Th17 cells (218,
221), an effect that was more pronounced in cultures of T cells
from women than from men (172). New data have extended these
observations in a vitamin D3 dose escalation study performed in
healthy controls during the UV-restricted winter months (213). As
supplementary vitamin D3 increased from 2000 to 8000 IU/day,
the mean serum 25-OHD rose from 30± 12 to 159± 29 nmol/L,
and the proportions of Th1 and Th17 cells in the peripheral blood
decreased. There appeared to be a threshold effect with at least
70 nmol/L of 25-OHD triggering a mean 40% decrease in circu-
lating Th17 cells in the healthy controls. Other studies found no
correlation between Th17 cells and 25-OHD in MS patients (222),
and no effect of supplementary vitamin D3 on Th17 cells in MS
patients (223). Why the human data are conflicting is not clear, but
vitamin D3 status at enrollment, vitamin D3 dose, dose frequency
(135), use of disease-modifying drugs, and timing of sampling
relative to estrogen cycling in women are potential confounding
factors. Nevertheless, given the strong animal modeling data and
some human in vivo data that are consistent with animal modeling,
it is reasonable to suggest that vitamin D may significantly influence
the emergence of an autoimmune disease phenotype by dampening
pathogenic Th17 cells and IL-17 synthesis.
VITAMIN D AND Th2 CELLS
Analyses of Th2 cells in vivo have also yielded inconsistent results.
Administering calcitriol to mice before EAE induction increased
the IL-4 transcripts in the lymph nodes and in the CNS compared
to the placebo controls (204). Also, targeted disruption of the IL-4
gene moderately decreased the protective function of calcitriol in
EAE (224). A subsequent report found no significant differences
between calcitriol-pretreated and placebo-pretreated B10.PL mice
with regard to IL-4 mRNA in the lymph nodes or the CNS after
immunization with MBP (182). There was also no effect of cal-
citriol on the IL-4 protein synthesis per Th2 cell. Another report
found administering calcitriol to Biozzi AB/H mice before EAE
induction had no effect on the IL-4-producing Th2 cell frequency
(206). Thus, there are some inconsistencies regarding IL-4 that
remain to be resolved. Since calcitriol inhibition of EAE decreased
slightly in IL-4-null mice, there may be some IL-4 contribution to
the mechanism (224), but it is possible that Th2 cells were not the
source of the protective IL-4.
The IL-5-producing Th2 cells have a pathogenic role in human
asthma. When CD4+ T cells from asthma patients were stim-
ulated with dust mite allergen in the presence of calcitriol, the
hormone decreased IL-5, IL-9, and IL-13 production (225). Cal-
citriol’s actions to promote IL-10-producing Treg cells in asthma
patients are discussed below.
VITAMIN D AND CD4+ T-CELL PROGRAMED CELL DEATH
EFFECTOR T-CELL APOPTOSIS AND AUTOIMMUNE-MEDIATED TISSUE
DAMAGE
When effector CD4+ T cells are no longer needed for anti-
microbial defense,programed cell death mechanisms remove them
to limit immune-mediated tissue damage. Several mechanisms
used by CD4+ Treg cells (197, 226), astrocytes and neurons (227,
228), and a few other types of cells to control effector CD4+ T cells
involve apoptosis induction. In individuals predisposed to autoim-
munity, it appears that effector CD4+ T cells resist cell death
mechanisms, proliferate, and continue to produce inflammatory
molecules that damage the host’s tissues.
The effector T lymphocytes from the T1D-susceptible NOD
mice were resistant to cell death signals. The resistance to cell
death mapped to a genomic region encompassing the Ctla4 gene,
which was defectively expressed on T cells from these mice (229).
In human autoimmunity, myelin-specific CD4+ T cells from MS
patients provide an example of defective cell death mechanisms
(230). These T cells were defective in the FAS–caspase 8 cell death
pathway (231) and the galectin-9–TIM-3 cell death pathway (232).
It was intriguing that myelin-specific T cells from MS patients
with benign disease had a significantly augmented galectin-9–
TIM-3 cell death pathway compared to MS patients with active
disease (Saresella et al., ECTRIMS 2011, Abstract P324). Moreover,
MS disease activity fluctuated seasonally, with a high frequency
of new lesions following a period of reduced ambient UV light
and vice versa (31). Taken together, the seasonal fluctuations in
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MS disease activity and disease activity-associated fluctuations
in T-cell apoptosis resistance hint at a possible causal relation-
ship between ambient UVB light, vitamin D3 supplies, myelin-
specific T-cell susceptibility to cell death, and demyelinating
disease activity.
VITAMIN D REGULATION OF EFFECTOR T-CELL APOPTOSIS
A causal relationship between calcitriol, myelin-specific T-cell
responsiveness to cell death signals, and demyelinating disease
activity has been demonstrated in the animal model of MS
(Figure 1B). In animals with EAE, calcitriol treatment in vivo
increased the susceptibility of pathogenic myelin-specific CD4+
T cells to extrinsic, CNS-derived apoptotic signals (207). This
treatment induced the pro-apoptotic gene encoding caspase-8-
associated protein, which is essential for FAS-mediated apoptosis,
and repressed cellular inhibitor of apoptosis protein 2 (cIAP-2), an
apoptosis inhibitor (209). Effector T-cell death is triggered in the
CNS by astrocyte- and neuron-mediated activation of the T-cell
FAS death pathway (227, 228, 233–235). In the calcitriol treatment
study, apoptotic CD4+ T cells were evident in CNS lesions and
IFN-γ production ceased by 12 h post treatment; within 1 day, the
CD4+ T-cell numbers were 60% reduced, correlating with abate-
ment of clinical disease signs by day 3 (208, 210). These T-cell
changes were not observed in the periphery or in vitro. A transient
increase in Helios+FoxP3+ Treg cells coincided with the loss of
effector T cells suggesting the Treg cells may have played an active
role in effector T-cell elimination (216). In the NOD model of T1D,
peripheral T cells were resistant to programed cell death signals,
and calcitriol treatment restored their sensitivity to these signals
(229, 236–238). These results support a direct calcitriol action on
effector T cells to promote sensitivity to apoptotic signals.
Vitamin D may also influence other cell death pathways in
effector CD4+ T cells. Treg cells expressing galectins can trigger
effector T-cell death via the TIM3 pathway (226). The N-linked
glycans, in particular terminal galactosyl residues, are essential for
galectin-9 binding to TIM3 and induction of cell death through
calpain and caspase-1 activation (239, 240). Importantly, calcitriol
enhanced α-mannosidase N -acetyl-glucosaminyl transferase 1,
the rate-limiting enzyme in N-linked glycan synthesis (241), UDP-
galactose: beta N -acetyl glucosamine-beta-1,3-galactosyl trans-
ferase, and calpain (209). Thus, calcitriol may improve T-cell
sensitivity to the galectin-9–TIM3–calpain cell death pathway,
which was impaired in MS patients (232). Together, the animal
modeling and human in vivo data linking vitamin D and calcitriol
with effector T-cell apoptosis suggest that vitamin D may signifi-
cantly influence the emergence of an autoimmune disease phenotype
by increasing effector CD4+ T-cell sensitivity to extrinsic cell death
signals.
VITAMIN D AND CD4+ T-REGULATORY LYMPHOCYTES
TREG LYMPHOCYTES IN AUTOIMMUNE DISEASE
CD4+ Treg cells are defined functionally by their ability to
limit prolonged effector T-cell activation, thereby preventing
autoimmune-mediated pathology (242). T lymphocytes that sup-
press autoimmunity were first demonstrated in mice (243–246).
Subsequently, their existence was confirmed in humans (247).
Several types of Treg cells exist differing in origin, phenotype,
and function. The most intensely studied are those for which
FoxP3 serves as the definitive transcription factor in lineage spec-
ification (248). One FoxP3+CD4+ Treg cell subset arises during
thymic development (tTreg), whereas another arises during TCR
engagement in the periphery (pTreg) (249). These FoxP3+CD4+
Treg cell subsets are non-functional in male scurfy mice and boys
with the multi-organ autoimmune disease immune-dysregulation
polyendocrinopathy enteropathy X-linked syndrome (IPEX), due
to loss-of-function mutations in the X-linked rodent Foxp3 and
human FOXP3 genes, respectively. The FoxP3 protein serves as a
biomarker for this Treg lineage.
The T-regulatory cell type 1 (Tr1) cells differ from
FoxP3+CD4+ Treg cells in origin, phenotype, and function (250).
The CD4+ Tr1 cells are peripheral memory T lymphocytes that are
anergic and do not express FoxP3 (251). Selective biomarkers for
Tr1 cells in humans and rodents are co-expression of integrin alpha
2 subunit (CD49b, a cell adhesion molecule) and lymphocyte acti-
vation gene 3 (LAG-3 or CD223, a negative regulator of effector
T-cell function) (252). Upon CD3 stimulation and co-stimulation
via the complement regulator CD46 in the presence of IL-2, the
CD4+ Tr1 cells rapidly proliferate and secrete large amounts of
IL-10 and TGF-β to exert suppressive function (253). The Tr1 cells
also release granzyme B to specifically lyse APC of myeloid origin,
effectively terminating further effector T-cell activation.
Functional defects in FoxP3+CD4+ Treg cells have been
described in multiple autoimmune diseases (254). Such defects
were first reported and confirmed in peripheral blood T cells from
MS patients (255, 256). Additional evidence emerged for reduced
CD4+ Treg cell generation in the thymus of MS patients (257,
258). The impairment correlated with reduced FoxP3 expression
in MS patient T cells (259, 260). Studies of FoxP3+CD4+ Treg cell
defects in MS have been reviewed (261, 262). Functional defects
in FoxP3+CD4+ Treg cells have also been extensively described
in T1D (263). Below, we review research suggesting calcitriol
enhances the expression of Helios, a positive regulator of FoxP3,
and of FoxP3 itself.
Functional defects in IL-10-producing CD4+ Tr1 cells have
also been described in many autoimmune diseases (250). An
early report demonstrated that T cells from T1D patients showed
extreme polarization toward a pro-inflammatory Th1 phenotype,
whereas the T cells from the non-diabetic, HLA-matched con-
trol subjects showed an extreme bias toward the IL-10-secreting
Treg phenotype (264). Functional defects in Tr1 cells have also
been extensively studied in MS. Stimulation of MS patient T cells
in vitro via CD3 and CD46 elicited very little IL-10 production
compared to controls (265). These findings have been confirmed
(261, 266, 267) and extended to a primate model of MS (268).
Functional defects in IL-10-producing CD4+ Tr1 cells have also
been described in asthma and rheumatoid arthritis (269). Below,
we review research suggesting calcitriol enhances the expression
of IL-10 and controls the Th1–Tr1 switch through modulation of
CD46, a positive regulator of IL-10.
CUTANEOUS UVB LIGHT EXPOSURE AND Treg LYMPHOCYTES
Cutaneous UVB light exposure and in situ vitamin D metabolism
may have a particularly important role in cutaneous Treg cell devel-
opment. Cutaneous UVB exposure promotes T-cell-mediated
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immunity to microbial pathogens; Finsen received the 1903 Nobel
Prize in Medicine for phototherapy of skin diseases (270). More
recently, the role of cutaneous UVB exposure in peripheral
immune tolerance has been recognized (271). The dual role of
UVB exposure illustrates how the vitamin D system may have
evolved to promote anti-pathogen responses at environmental
interfaces, and subsequently to terminate these responses before
the tissues sustain immune-mediated damage.
Ground-breaking animal modeling studies revealed how cuta-
neous UVB exposure promotes peripheral immune tolerance at
the molecular level (272). Infection increased keratinocyte expres-
sion of receptor-activator of NF-kappaB ligand (RANKL). In
transgenic mice with keratinocytes overexpressing RANKL, the
keratinocytes signaled receptor-activator of NF-kappaB (RANK)-
expressing Langerhans cells to induce IL-10-producing pTreg cells
in the skin-draining lymph nodes. These pTreg cells suppressed
the contact hypersensitivity response to cutaneous antigens in
the original host animal and in adoptive transfer host animals.
Furthermore, when skin was grafted from WT mice or Tnfrsf11a-
null mice lacking RANKL onto WT host animals, UVB irradiation
of the WT but not the Tnfrsf11a-null skin graft prevented graft
rejection. These experiments established that keratinocyte RANKL
expression was necessary for UVB exposure to induce IL-10-
producing pTreg cells specific for the grafted skin to maintain
peripheral tolerance.
Importantly, cutaneous UVB exposure promoted pTreg cell
development by a calcitriol and VDR-dependent mechanism
(273). Keratinocytes have a complete vitamin D3 biosynthetic
pathway which when stimulated by infection, injury, or light pro-
duced 2–5 nmol/L of calcitriol in situ (159, 274), about 20- to
50-fold higher than calcitriol in the blood plasma of non-pregnant
women (275). Furthermore, calcitriol transcriptionally activated
the murine (Tnfrsf11a) and human (TNFRSF11A) genes encoding
RANKL through highly evolutionarily conserved and functionally
active VDREs in the promoter regions, as described in osteoblasts
(276–278), murine and human T lymphocytes (279, 280), and
keratinocytes (127). In the animal model of cutaneous hyper-
sensitivity, topically applied calcitriol mimicked cutaneous UVB
exposure by inducing keratinocyte RANKL expression and stimu-
lating IL-10-producing pTreg cells by a mechanism that was VDR-
dependent (281, 282). Cell labeling studies demonstrated that the
pTregs trafficked between the skin, the skin-draining lymph nodes,
and the circulation (283). Calcitriol suppressed T-cell expression
of the gut-homing receptors and increased T-cell expression of
CC chemokine receptor 10, enabling T-cell migration to the skin-
specific chemokine CCL27 produced by keratinocytes (100). In
summary, seminal studies of experimental UVB-induced periph-
eral tolerance in rodents established that a calcitriol- and VDR-
dependent pathway exists involving (i) keratinocyte synthesis of
calcitriol and stimulation of RANKL expression, (ii) signaling to
RANK-expressing Langerhans cells, (iii) movement of the Langer-
hans cells to the skin-draining lymph nodes, (iv) induction of cuta-
neous antigen-specific, IL-10-producing pTreg cells, and finally (v)
movement of the pTregs to the skin to prevent cutaneous antigen-
specific effector T cells from degrading the epidermal barrier.
New research has begun to translate this knowledge to humans.
Subjects from the North of Scotland who had skin disease were
recruited between December and March for a phototherapy
study (284). The subjects had a mean baseline 25-OHD level
of 34 nmol/L and 0.5% FoxP3+ pTreg cells as a percentage of
blood CD3+ T cells. After 4 weeks of phototherapy, the mean 25-
OHD was 78 nmol/L and the FoxP3+ pTreg cell percentage was
1.6%. Another study demonstrated that UVB exposure substan-
tially expanded pTreg cell numbers in the skin, and these skin pTreg
cells appeared to have derived from peripheral immune organs
(285). The studies in animals and humans implicating calcitriol
as a positive regulator of the Tnfsf11a and Tnfrsf11a genes and
cutaneous FoxP3+ pTreg cell induction suggest that during peri-
ods of light starvation, phototherapy may be a particularly efficient
method of influencing the emergence of an autoimmune disease phe-
notype by increasing CD4+CD25+FoxP3+ Treg cell development
and suppressive function.
VITAMIN D AND THE IL-10–IL-10R PATHWAY
Interleukin-10 is a particularly important anti-inflammatory
cytokine that protects the CNS (286), the airway (287), the gas-
trointestinal tract (288), and other tissues from immune-mediated
pathology (289, 290). Disruption of the IL-10–IL-10R signaling
pathway results in severe inflammatory disease (291).
Early research in two rodent models suggested that calcitriol
promotes the development of IL-10-producing Treg cells. In the
EAE model, suppressor T cells inhibited disease by an IL-10-
dependent mechanism (292, 293). Calcitriol inhibited EAE not by
blocking T-cell priming in the periphery or effector T-cell traffick-
ing into the CNS, but instead by inducing Rag-1 gene-dependent
regulatory lymphocytes (182). Subsequent work demonstrated
that activation of human and mouse T cells in the presence of
dexamethasone and calcitriol in vitro yielded IL-10-producing
Tr1 cells (294). Furthermore, vitamin D3 or calcitriol-mediated
inhibition of EAE required functional Il10 and Il10R genes, bidi-
rectional IL-10–IL-10R signaling between hematopoietic and non-
hematopoietic cells (205), and a functional Vdr gene in CD4+ T
cells (184). Calcitriol had no effect on IL-10R expression (205).
In the NOD model of T1D, calcitriol increased the frequency of
Treg cells in the pancreatic lymph node (295), and global Vdr
gene inactivation decreased the frequency of these cells (296). A
positive calcitriol influence on T-cell IL-10 synthesis was observed
in vitro (297). These animal studies suggested calcitriol may inhibit
autoimmune disease at least in part through a VDR-dependent
action on CD4+ T cells to induce IL-10-producing Treg cells.
There is limited information on a possible direct link between
vitamin D and IL-10 in humans. An early study found a sea-
sonal variation in the cord blood IL-10 level that correlated
directly with the 25-OHD for infants born at 51°N (298). The
25-OHD levels were 99% higher and IL-10 was 43% higher in
samples obtained in the summer compared to samples obtained
in the winter. Investigations of calcitriol effects on IL-10 synthe-
sis by human T cells activated in vitro have yielded conflicting
results with reports of both enhancement (172, 221) and inhibi-
tion (179). A very interesting recent study examined the effect of
adding 25-OHD3 to cultures of lymphocytes from healthy con-
trols and from hereditary vitamin D-dependent rickets (HVDRR)
patients with loss-of-function mutations in the VDR gene (189).
The 25-OHD3 increased IL-4, IL-10, and IFN-γ production from
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control lymphocytes, but not patient lymphocytes, demonstrat-
ing calcitriol synthesis and VDR dependence of IL-10 induction
in vitro.
VITAMIN D AND Treg CELLS IN ASTHMA
Asthma research has yielded important new insights regarding
vitamin D and Treg cells (299). One of them relates to the bal-
ance between immunity to pathogens and self-tolerance. Calcitriol
ingestion by healthy volunteers and calcitriol addition to cultures
increased CD4+ T-cell IL-10 secretion and TLR9 expression (300).
Adding TLR9 agonists to the cultures decreased T-cell IL-10 pro-
duction and suppressive function. These findings are significant
because they suggest pathogen signaling through TLR9 could sus-
pend T-cell suppressive function temporarily until an infection
has been cleared. A second insight relates to calcitriol enhance-
ment of T-cell surface molecules that dampen immune responses.
In this case, calcitriol up-regulated CD200 on human peripheral
and respiratory tract CD4+ T cells in vitro, and there was a trend
toward up-regulation in vivo in healthy, but not asthmatic indi-
viduals (301). CD200 is an immunoglobulin superfamily member;
it imparts a unidirectional negative signal to suppress innate and
adaptive immune responses.
Yet another insight from the asthma research relates to
the distinction between CD4+FoxP3−IL-10+ Tr1 cells and
CD4+FoxP3+IL-10− Treg cells. Systemic vitamin D status cor-
related directly with airway levels of IL-10 and CD4+FoxP3+
T cells in pediatric asthma patients and in healthy controls
(302, 303). In cultures of human peripheral blood T cells,
adding calcitriol at moderate levels (10−8 mol/L) increased the
frequency of CD4+IL-10+ Tr1 cells, whereas higher calcitriol
(10−6 mol/L) increased the frequency of CD4+FoxP3+ T cells.
However, there was little co-expression of FoxP3 and IL-10, and
IL-10 impaired calcitriol-mediated enhancement of FoxP3. Mod-
ulating the cytokine environment to include TGF-β together
with calcitriol favored CD4+FoxP3+ T-cell outgrowth (304). The
CD4+IL-10+ and CD4+FoxP3+ T-cell populations had equivalent
suppressive activity in vitro, although their suppressive mecha-
nisms were IL-10-dependent and IL-10-independent, respectively.
These data are highly significant for two reasons. First, they
demonstrate that the vitamin D system supports two phenotypi-
cally and functionally distinct Treg cell populations. Secondly, they
suggest that as infections are resolved, calcitriol-supported devel-
opment of CD4+FoxP3−IL-10+ Tr1 cells and CD4+FoxP3+IL-
10− Treg cells may proceed in an ordered sequence to per-
form slightly different functions, for example attenuating innate
and adaptive immune responses by IL-10-dependent and IL-10-
independent mechanisms, respectively. Many interesting ques-
tions remain regarding the underlying mechanisms of Treg cell
immune response regulation in the airway, and the generality of
these findings to other interfaces between the environment and the
host organism where immunity to pathogens must be balanced
with self-tolerance.
VITAMIN D AND FOXP3+ Treg LYMPHOCYTES
Above, we summarized early animal modeling data suggesting cal-
citriol promoted the development of IL-10-producing Treg cells
before FoxP3 expression was in use as a Treg biomarker. New
animal modeling data suggest calcitriol may be a positive regulator
of the murine FoxP3 gene itself (185), and of the Ikzf2 gene encod-
ing Helios (216), a transcription factor that binds to the FoxP3
promoter and stimulates its transcription (305–307).
CD4+Foxp3+ Treg cell studies in humans are scarce and
conflicting. Two reports correlated 25-OHD with circulating
CD4+Foxp3+ Treg cell percentages (308, 309). One study cor-
related the suppressive capacity of the CD25+CD4+ Treg cells
with serum 25-OHD levels in MS patients (222), but this associa-
tion could not be substantiated upon vitamin D3 supplementation
(223). A more recent study correlated seasonal increases in 25-
OHD and calcitriol in healthy men with increased Treg cell Foxp3
expression, a drop in memory CD4+CD45RO+ T cells, a reduced
capacity for T-cell pro-inflammatory cytokine production, and
increased CCR4, CCR6, CLA, CCR9, and CCR7 levels for homing
to skin, gut, and lymphoid tissue (310). Seemingly contradictory
results were reported for infants whose 25-OHD levels and T-cell
subsets in cord blood showed no correlations (311). Potential con-
founders in human studies are differences in phenotypic markers
used in the analyses, vitamin D3 status when beginning vita-
min D3 supplementation, supplementation protocols (135), use
of disease-modifying drugs in patients, and timing of sampling
relative to estrogen cycling in women.
Examining human T cells in culture documented an influ-
ence of calcitriol on FoxP3 (Figure 1C). Activation of human
CD4+CD25− T cells in vitro in the presence of calcitriol resulted
in greater numbers of CD4+CD25+FoxP3+ Treg cells (221),
particularly for female T cells (172). Addition of calcitriol to
human CD4+CD25− T-cell cultures increased CTLA4 (CD152)
and FoxP3 protein expression, the latter requiring the presence
of IL-2 (218). The increase in CTLA4 and FoxP3 protein expres-
sion was confirmed for MS patient T cells (219), and the CTLA4
increase was confirmed for T1D patient T cells (220). The sup-
pressive function of the calcitriol-induced CD4+CD25+FoxP3+
Treg cells was confirmed in many reports (218, 220, 221, 312).
Calcitriol positive regulation of CTLA4 is critically important,
because this protein is an essential negative regulator of immune
responses (313, 314). Humans who were heterozygous for loss-of-
function mutations in the Ctla4 gene developed a highly penetrant
autoimmune syndrome with strong similarity to IPEX. Specifi-
cally, they displayed loss of CD4+FoxP3+ Treg cell suppressive
function, hyperactivation of effector T cells, lymphocyte infil-
tration of multiple target organs, and fatal autoimmune disease.
CTLA4 strips CD80 and CD86 from the APC by endocytosing and
degrading these proteins to block their co-stimulation of CD28
on T cells (315). Calcitriol enhancement of this mechanism may
account in part for the hormone’s actions as an immune response
terminator.
Intriguing new data complemented the rodent data (185) and
revealed that calcitriol increased human FOXP3 gene expression
by a transcriptional mechanism (217). The human FOXP3 and
murine Foxp3 genes share homology in a conserved non-coding
sequence (+1714 to +2554 relative to the FOXP3 transcrip-
tional start site) that functions as an enhancer (316). Within
this enhancer region, investigators identified three VDREs that
enhanced promoter activity in a calcitriol-dependent manner
(217). Moreover, T-cell stimulation through CD3 and CD28 in
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the presence of IL-2 and calcitriol generated CD4+CD25+FoxP3+
Treg cells that inhibited target CD4+ T-cell proliferation by a cell
contact- and FOXP3-dependent mechanism. Collectively, the data
demonstrating calcitriol enhancement of Ikzf2, FOXP3, and Ctla4
gene expression suggest that vitamin D may significantly influence
the emergence of an autoimmune disease phenotype by increasing
CD4+CD25+FoxP3+ Treg cells and/or their suppressive function.
VITAMIN D, CD46, AND IL-10-PRODUCING Tr1 LYMPHOCYTES
Important new research into the function of CD46 has
demonstrated the existence of a calcitriol-mediated Th1–Tr1
switch controlling the delicate homeostatic balance between the
FIGURE 2 | A proposedTh1–Tr1 bi-stable biological switch bridging two
immune states, pro-inflammatory and anti-inflammatory.
(A) A theoretical diagram of two opposing immune states [adapted from a
generalized bi-stable switch diagram (302)]. Each circle represents T cells
that are in a stable biological state characterized by a particular gene
regulatory network and capable of responding to external stimuli in a
biologically appropriate manner. Biological barriers impede transitions
between the pro- and anti-inflammatorystates. Each biological state is
capable of reinforcing its own state, denoted as lines terminating in arrows,
and inhibiting the opposing state, denoted as blocked lines. External
stimuli, for example pathogens, hormones, cell-cell interactions, and
soluble mediators serve as switch inputs to drive a transition. For example,
signals 1 and 2 can be organized as “1 or 2”, “1 and 2”, or “1 not 2” to
trigger a dynamic transition between the two states. (B) The proposed
Th1–Tr1 switch appears to have the qualities of a bi-stable biological switch.
The Th1 cytokine IFN-γ and the Tr1 cytokine IL-10 impede the development
of Tr1 and Th1 cells, respectively. The autocrine growth factors IL-2 and IL-10
reinforce the survival and proliferation of Th1 and Tr1 cells, respectively.
Diminishing pathogen, sensed through TLR molecule engagement (280),
maturation of the pathogen-specific immune response, sensed through
CD46 molecule engagement by C3b and C4b (299, 300), and accumulating
calcitriol in the microenvironment, sensed through the VDR in Th1 cells,
provide the external stimuli to alter the dynamics of the system and drive
the transition to the Tr1 biological state. Helios may be a biomarker of
effector T cells undergoing a transition to a tolerant state (183). Calcitriol
increased Helios in CD4+ T cells at the beginning of a calcitriol-induced EAE
disease remission (144), and was recently identified as an inhibitor of Il2
gene transcription by an epigenetic silencing mechanism (184).
pro-inflammatory and anti-inflammatory states (Figure 2). CD46
and its murine analog complement receptor 1-related protein Y
(Crry) are transmembrane glycoproteins that bind complement
fragments C3b and C4b, and function as T-cell costimulatory
molecules (269). Temporal processing of two alternatively spliced
CD46 cytoplasmic tails, Cyt1 and Cyt2, served as a molecular
rheostat controlling activation and de-activation of human T-
cell responses (317). Co-engagement of the TCR and CD46 first
enhanced Th1 cell effector function (318). However, as IL-2 accu-
mulated, CD46 cytoplasmic domain interactions with the serine–
threonine kinase SPAK promoted effector Th1 cell switching to a
Tr1 phenotype with low IL-2 production, high IL-10 production,
and the capability to suppress bystander T-cell activation. Thus,
CD46 served as a molecular link between complement activation
and a Th1–Tr1 switch for immune response termination (269).
This switch was defective in MS (265, 266), asthma (319), and
rheumatoid arthritis patient T cells (318), effectively locking the
immune response in an interminable pro-inflammatory state.
Calcitriol profoundly amplified the Th1–Tr1 switch in vitro in
T cells from healthy donors and patients with MS (219). Calcitriol
also amplified this switch in vitro in T cells from T1D patients,
imprinting the T cells with an IL-10-producing Tr1 phenotype,and
modulating surface expression of chemokine receptors to enable
homing to inflamed sites (220, 312). Determining whether this
switch functions in vivo is a high priority goal. The emerging
data suggest that vitamin D may significantly influence the emer-
gence of an autoimmune disease phenotype by controlling a Th1–Tr1
switch that provides a bridge between two apparently stable immune
states, pro-inflammatory and anti-inflammatory. The calcitriol-
driven Th1–Tr1 switch is of utmost importance to autoimmune
disease, because each state appears to be self-reinforcing and capa-
ble of blocking the opposing state (Figure 2). Multistable switches
are known to play an important role in hematopoietic cell fate
decisions controlled by gene regulatory networks (320), and hor-
mones are known to be of paramount importance in controlling
these networks.
Calcitriol enhancement of the transcription factor Helios may
also be important to the Th1–Tr1 switch. Calcitriol treatment tran-
siently induced CD4+Helios+ T cells in the CNS of mice with EAE
prior to the loss of pathogenic CD4+ T cells from the CNS and the
onset of remission (216). New data show Helios was a marker for
peripheral T cells that are being driven to tolerance in response to
a genuine autoantigen in autoimmune gastritis (321). Helios was
identified as a key inhibitor of Il2 gene transcription in Treg cells
(322); it repressed the Il2 locus through epigenetic modifications
that included histone deacetylation.
Given the importance of pathways downstream of calcitriol sig-
naling to the Th1–Tr1 switch and immune response termination, it
is valuable to consider how those pathways could be compromised.
CD46 is the receptor for the T lymphotropic human herpesvirus-
6; the virions bind CD46 and trigger endocytosis (323). Whether
pathogen-mediated CD46 removal would undermine calcitriol
action by disabling the Th1–Tr1 switch is not known. Geneti-
cally determined defects in IL-10 production and IL-10R signaling
would be downstream of a calcitriol-mediated increase in Tr1 cells;
both defects were linked to an increased autoimmune disease risk
(324–329). The IL-10R signals through tyrosine kinase 2 (TYK2)
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and Janus kinase-1 (330). A novel missense mutation in the TYK2
gene was linked to an increased risk of MS (329). In addition,
recombinant hIL-10 did not inhibit proliferation of CD4+ T cells
from MS patients; the IL-10R signaling pathway was blocked at the
point of STAT3 activation in these cells (267). Defective IL-10R
signaling downstream of calcitriol action to induce Tr1 cells could
compromise this vitamin D-mediated protective mechanism.
CONCLUSION AND FUTURE RESEARCH DIRECTIONS
This review article sought to summarize and integrate research
on vitamin D and CD4+ T-lymphocyte biology in an effort to
develop a new understanding of the molecular etiology of autoim-
mune disease. There is a large, latitude-linked, non-transmissible
environmental component that acts at the population level to
determine the emergence of an autoimmune phenotype, given
an autoimmune disease-susceptible genotype. Diverse and com-
pelling evidence suggests that this environmental component is
ambient UVB light exposure catalyzing cutaneous vitamin D3
formation. Importantly, this environmental component exerts a
>100-fold influence on the risk of multiple autoimmune diseases,
and on disparate populations with distinct genotypes, dietary
habits, and exposures to infectious and commensal organisms,
larger than the influence of the strongest autoimmune susceptibil-
ity locus (MHCII genes; approximately fivefold) or the infectious
organism, EBV (approximately two to threefold).
The strength and universality of ambient UVB light and vit-
amin D3 as autoimmune disease risk factors, the vitamin D
hormone’s established role as a transcriptional regulator of gene
expression, and the role of CD4+ T lymphocytes as autoimmune
disease initiators and suppressors provided the rationale for closely
examining calcitriol regulation of CD4+ T-lymphocyte function
in this review. The conclusions supported by experimental evi-
dence are presented in Box 1. These conclusions address the
Bradford Hill criterion of a plausible biological mechanism that
coheres with known biological facts (115). This evidence has con-
tributed to a greater functional and mechanistic understanding of
the molecular etiology of autoimmune disease, one of the major
challenges in modern immunobiology.
Important questions remain. Regarding paracrine calcitriol sig-
naling to CD4+ T cells, more work is needed in vivo to understand
the cellular sources of calcitriol, the signals and kinetics that
induce and terminate calcitriol synthesis and their relationship
to infectious organisms. More work is also needed to under-
stand the signals and kinetics that induce and terminate VDR and
CYP24A1 gene expression in specific types of CD4+ T cells in vivo,
and how gender influences calcitriol responsiveness and calcitriol
turnover. Finally, we must learn what factors and mechanisms dis-
rupt paracrine signaling (genetic lesions, drugs, oxidative damage
to enzymes, epigenetic dysregulation).
A second and related high priority is probing a possible vit-
amin D influence on thymic selection. Such an influence would
have high significance for our understanding of the molecular eti-
ology of autoimmune disease risk acquisition and our effort to
correctly time disease prevention efforts. The data correlating sea-
sonal variation in thymic output inversely with vitamin D status
await replication. Assuming reproducibility, mechanistic inquiry
will be needed to distinguish potential impacts on thymopoiesis
and positive selection from negative selection, and to decipher the
calcitriol-regulated genes that influence these processes.
Other questions relate to calcitriol actions on effector CD4+ T
cells in vivo. Calcitriol suppression of Il17 transcription and IL-17
protein synthesis has been studied mechanistically in rodents with
conflicting results. It will be important to clarify the biochem-
istry of Il17 transcriptional and post-transcriptional regulation
by calcitriol in Th17 cells in vivo in the context of different
autoimmune disease settings where physiologically relevant tis-
sue architecture and cell and cytokine microenvironments exist.
Other open questions concern the biochemistry of the effector
Box 1 Summary of main conclusions regarding vitamin D, CD4+ T lymphocytes, and autoimmune disease.
An autoimmune disease phenotype emerges when modifiable environmental stressors act on a disease-susceptible genotype, and exposure
to at least one environmental stressor is increasing.
Vitamin D is probably the environmental factor with the greatest influence on the emergence of an autoimmune disease phenotype given
a disease-susceptible genotype.
At high latitudes, there is a period of “light starvation” when vitamin D synthesis is negligible; the higher the latitude, the greater is the light
starvation period.
Paracrine calcitriol signaling to CD4+ T cells within tissues is likely the major pathway by which sunlight as an environmental factor exerts
its influence on the emergence of an autoimmune disease phenotype.
The VDR–RXR complex regulates gene expression in a cell type-specific manner through VDRE in calcitriol-responsive genes.
The hormonal form of vitamin D may influence thymic selection, which would have a significant influence on autoimmune disease risk
acquisition and the timing of autoimmune disease prevention initiatives.
The hormonal form of vitamin D may significantly influence autoimmune disease risk and severity by (i) dampening pathogenic Th17 cell
IL-17 synthesis, (ii) increasing effector CD4+ T-cell sensitivity to extrinsic cell death signals, (iii) promoting CD4+CD25+FoxP3+ Treg cell and
CD4+IL-10+FoxP3− Tr1 cell development and suppressive function, (iv) amplifying a Th1–Tr1 switch that may bridge two apparently stable
immune states, an anti-pathogen pro-inflammatory state and a self-tolerant anti-inflammatory state.
During periods of light starvation, phototherapy to increase FoxP3+Treg cell development may be a particularly efficient method of influencing
autoimmune disease risk and severity.
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CD4+ T-cell programed cell death pathways that are influenced
by calcitriol, and the cellular source and timing of the extrinsic cell
death signaling.
Another very high priority is probing how vitamin D pro-
motes CD4+FoxP3+IL-10− Treg and CD4+FoxP3−IL-10+ Tr1
cell development, stability, and suppressive function. Unanswered
questions relate to the biochemical mechanisms for the proposed
calcitriol up-regulation of Ikzf2, Il10, Ctla4, and CD200 gene tran-
scription, and the relationship between VDR and FOXP3, how
each gene may impact the other’s expression and the kinetics and
stability of the interaction.
Additional questions concern the molecular details of the pro-
posed Th1–Tr1 switch. Whether this switch functions in vivo in
the context of different autoimmune diseases is a top priority
question. Moreover, questions remain regarding the precise bio-
chemical details of the switch, the signals that trigger it, how the
signals are transduced to the nucleus, how the gene expression
program is altered by those signals, and exactly how calcitriol
amplifies the switch. This molecular knowledge is needed to envi-
sion and probe how pathogen-mediated engagement of CD46
might compromise the switch. Mathematical modeling of the
switch may be helpful to envision interactions between envi-
ronmental pathogens, the sun-sensitive hormone, the pathogen-
specific immune response, immune response termination, and
self-tolerance maintenance.
Sir Austin Bradford Hill suggested minimal criteria for judg-
ing the causal nature of relationships between environmental
factors and disease (115). Many experts believe the experimen-
tal evidence linking vitamin D3 with autoimmune disease risk
is sufficiently compelling to satisfy eight of the nine criteria (6).
Perhaps, the most important unanswered question derives from
Bradford Hill’s ninth criterion, experiment. Would an intervention
that substantially elevates circulating 25-OHD3 prevent or change
autoimmune disease in light-starved populations with low vita-
min D status? Now would be a good time for autoimmune disease
researchers to address this unanswered question collaboratively.
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